IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.

Abstract

ABSTRACT:

High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.

• Authors: Lih En Hong, Mihir D Wechalekar, Monika Kutyna, Annabelle Small, Kelly Lim, Chloe Thompson-Peach, Joule J Li, Rakchha Chhetri, Hamish S Scott, Anna Brown, Christopher N Hahn, David T Yeung, Salvia Sajid, Nirmal Robinson, Ranjeny Thomas, Susan Branford, Richard J D'Andrea, Saumya E Samaraweera, Mrinal Patnaik, Susanna Proudman, Daniel Thomas, Chung Hoow Kok, Mithun V Shah, Devendra K Hiwase
• Journal: Blood (Blood) Vol. 143 Issue 18 Pg. 1873-1877 (May 02 2024) ISSN: 1528-0020 [Electronic] United States
• PMID: 38457663 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
• Copyright: © 2024 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Chemical References

• Isocitrate Dehydrogenase
• IDH1 protein, human

Topics

• Humans
• Arthritis, Rheumatoid (immunology, genetics)
• Immunity, Innate
• Isocitrate Dehydrogenase (genetics)
• Mutation
• Male
• Female
• Middle Aged
• Aged